ClinicaliQ Trial Snapshot
- Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07230288.
- What is being tested: ABBV-142, an investigational therapeutic agent, is being evaluated for its safety profile and effects on disease progression in adult patients with idiopathic pulmonary fibrosis (IPF).
- Patient eligibility overview: The trial enrolls adult participants with a confirmed diagnosis of IPF; specific inclusion/exclusion criteria regarding disease stage, lung function, and prior treatments will determine individual suitability.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time. The main goals of the study…
Eligibility Snapshot
- : - Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verification of usual interstitial pneumonia(UIP) or probable UIP.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.